Why it matters now
The COVID period dramatically accelerated the adoption and innovation in point-of-care diagnostics, creating new infrastructure and consumer awareness. As the immediate pandemic demand recedes, businesses need to discern which areas of this market retain momentum and why. Understanding the underlying drivers of sustained growth, such as chronic disease management, infectious disease surveillance beyond COVID, or home testing trends, is crucial. Companies risk misallocating resources if they fail to identify the enduring shifts versus temporary boosts. Strategic clarity is essential to capitalize on lasting opportunities and avoid over-investing in diminishing segments.
Who is exposed
Diagnostic manufacturers face revenue adjustments as pandemic-related product demand normalizes. Clinical laboratories may see shifts in testing volumes and types, requiring adaptation of services. Urgent care centers and primary care providers are exposed to changes in patient expectations for rapid, on-site testing. Companies involved in supply chains for diagnostic components and consumables will experience evolving demand patterns, impacting their production and distribution planning.
Most relevant for: Market Analyst, Investment Manager, Business Strategist
What this Viewpoint covers
- Which infectious disease testing areas show continued demand beyond COVID?
- How are chronic disease management applications driving POC growth?
- What role are home-based and consumer-facing POC tests playing?
- Which technological advancements are fueling sustained market expansion?
- How are regulatory frameworks influencing adoption in various settings?
Signals to watch
- Increased investment in non-COVID infectious disease POC platforms.
- Expansion of chronic disease management programs incorporating POC.
- New product launches for home-based diagnostic applications.
- Changes in reimbursement policies for specific POC test categories.
Decisions it supports
- Where to prioritize R&D investments for future diagnostic products.
- Which market segments offer the most sustainable growth opportunities.
- How to adjust manufacturing capacity and supply chain strategies.
How it is built
Prepared after your order from dated public sources - such as medical devices & healthcare filings and announcements, regulatory records, trials, patents and trade data, where relevant - and our market model. Reported facts are cited, estimates are labelled and our assessment is marked as such, following our research method. You receive our verdict, the evidence, who is exposed, the signals to watch and recommended actions, within 24 hours.
Questions
Is the demand for all point-of-care diagnostics declining post-COVID?
While some specific COVID-related testing volumes have adjusted, the broader point-of-care diagnostics market is not uniformly declining. Many segments, particularly those addressing chronic diseases, other infectious diseases, and consumer health, are demonstrating sustained or new growth, driven by convenience and rapid results.
Which types of point-of-care tests are expected to see continued growth?
Growth is anticipated in areas such as respiratory pathogen panels, sexually transmitted infection testing, and diagnostics for chronic conditions like diabetes and cardiovascular disease. Home-based testing and tests integrated into digital health platforms are also key areas of sustained expansion.
How should our company adapt its product portfolio?
Companies should evaluate their portfolio to identify products aligned with these enduring growth drivers. This may involve shifting focus from solely pandemic-driven solutions to developing or acquiring tests that address chronic disease management, broader infectious disease surveillance, or consumer health needs, emphasizing ease of use and connectivity.